3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Sarcopenia
1
Patient Compliance
1
Overweight
1
Obesity
1
Motor Activity
1
Malnutrition
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Anatomic Stage I Breast Cancer AJCC v8
1
Advanced Malignant Solid Neoplasm
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Nutrition Assessment
×
90 days
×
Clear all
No trials found.